Mitsuyuki Hiromoto
Yamaguchi University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mitsuyuki Hiromoto.
Circulation | 2002
Shinichi Itoh; Seiji Umemoto; Mitsuyuki Hiromoto; Yoichi Toma; Yasuaki Tomochika; Shumpei Aoyagi; Masakazu Tanaka; Takashi Fujii; Masunori Matsuzaki
Background—Increased vascular oxidative stress induced by hyperlipidemia may alter the phenotype of vascular smooth muscle (SM) cells and play a crucial role in the progression of atherosclerosis. To clarify the mechanisms underlying vascular dysfunction and oxidative stress in hypercholesterolemia, we compared the effects of antioxidant probucol with those of pravastatin on aortic stiffness, phenotypic modulation, oxidative stress, and NAD(P)H oxidase essential subunit p22phox expression in aortic medial SM cells of cholesterol-fed rabbits by using color image analysis of immunostained sections. Methods and Results—Japanese white male rabbits were fed either normal chow or 1% cholesterol diet for 14 weeks. After the first 7 weeks, cholesterol-fed rabbits were further divided into 3 groups: those fed with cholesterol feed only and those additionally given pravastatin (10 mg/d) or probucol (1.3 g/d) for the last 7 weeks. Within 7 weeks of treatment, probucol improved aortic stiffness more effectively than did pravastatin, inhibiting phenotypic modulation by selectively upregulating contractile-type SM myosin heavy chain isoform SM2 and by reducing both p22phox and superoxide content in medial SM cells of cholesterol-fed rabbit aorta. No significant differences in cholesterol levels, superoxide content, and endothelial NO synthase levels in the intima, aortic morphology and fibrosis, and synthetic-type myosin heavy chain in medial SM cells were observed between the 2 drug-treated groups. Conclusions—These results suggest that oxidative stress and SM2 in medial SM cells might be important factors for vascular dysfunction, and strategies aimed at blocking NAD(P)H oxidase and upregulating SM2 may have therapeutic potential against the progression of atherosclerosis in hypercholesterolemia.
Japanese Circulation Journal-english Edition | 1996
Mitsuyuki Hiromoto; Yoichi Toma; Yasuaki Tomochika; Seiji Umemoto; Masunori Matsuzaki
Japanese Circulation Journal-english Edition | 2008
Yusaku Fukumoto; Takafumi Hiro; Takashi Fujii; Mitsuyuki Hiromoto; Masakazu Tanaka; Michio Yamada; Masunori Matsuzaki
Circulation | 2007
Yusaku Fukumoto; Takafumi Hiro; Takashi Fujii; Mitsuyuki Hiromoto; Masakazu Tanaka; Masunori Matsuzaki
Circulation | 2007
Yusaku Fukumoto; Takafumi Hiro; Takashi Fujii; Mitsuyuki Hiromoto; Masakazu Tanaka; Michio Yamada; Masunori Matsuzaki
Journal of Cardiac Failure | 2005
Mitsuyuki Hiromoto; Hiroshi Iwamoto; Masakazu Tanaka; Michio Yamada
Japanese Circulation Journal-english Edition | 2002
Shinji Kawahara; Shinichi Itoh; Mitsuyuki Hiromoto; Masa Tanaka; Takashi Fujii; Masunori Matsuzaki; Seiji Umemoto
Japanese Circulation Journal-english Edition | 2002
Shinichi Itoh; Mitsuyuki Hiromoto; Masa Tanaka; Shinji Kawahara; Takashi Fujii; Masunori Matsuzaki; Seiji Umemoto
Japanese Circulation Journal-english Edition | 1996
Mitsuyuki Hiromoto; Yoichi Toma; Yasuaki Tomochika; Shumpei Aoyagi; Seiji Umemoto; Masunori Matsuzaki
Japanese Circulation Journal-english Edition | 1995
Shumpei Aoyagi; Yuichiro Wasaki; Yoichi Toma; Yasuaki Tomochika; Ikuo Tokisawa; Takashi Tone; Mitsuyuki Hiromoto; Takahito Yonezawa; Chieko Morikuni; Kazuya Murata; Masunori Matsuzaki